The presence of the TMPRSS2::ERG fusion in prostate cancer is associated in part with cancer recurrence, and commonly corresponds to a more aggressive malignancy and overall poorer clinical prognosis [31,54,218,219,220,221,222]. This evidence concerns the gene ERG and Familial prostate cancer.